Zacks: Analysts Expect Orthofix International N.V. (OFIX) Will Announce Quarterly Sales of $112.30 Million
Brokerages predict that Orthofix International N.V. (NASDAQ:OFIX) will post $112.30 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Orthofix International’s earnings. The lowest sales estimate is $111.40 million and the highest is $113.20 million. Orthofix International reported sales of $108.54 million in the same quarter last year, which indicates a positive year over year growth rate of 3.5%. The company is scheduled to report its next quarterly earnings report on Monday, February 26th.
According to Zacks, analysts expect that Orthofix International will report full-year sales of $112.30 million for the current financial year, with estimates ranging from $428.40 million to $430.30 million. For the next financial year, analysts forecast that the firm will report sales of $451.47 million per share, with estimates ranging from $446.50 million to $456.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Orthofix International.
Orthofix International (NASDAQ:OFIX) last released its quarterly earnings data on Monday, October 30th. The medical device company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.41 by $0.01. Orthofix International had a return on equity of 10.26% and a net margin of 0.33%. The company had revenue of $105.30 million during the quarter, compared to the consensus estimate of $100.67 million. During the same period last year, the company earned $0.36 EPS. Orthofix International’s revenue for the quarter was up 6.9% on a year-over-year basis.
In other Orthofix International news, insider Bradley V. Niemann sold 6,956 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $49.44, for a total value of $343,904.64. Following the transaction, the insider now directly owns 40,178 shares of the company’s stock, valued at $1,986,400.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Rice Doug sold 7,353 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $49.46, for a total value of $363,679.38. Following the completion of the transaction, the chief financial officer now directly owns 44,743 shares in the company, valued at $2,212,988.78. The disclosure for this sale can be found here. Insiders sold 24,109 shares of company stock worth $1,220,840 over the last three months. Insiders own 5.60% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Oakview Capital Management L.P. purchased a new position in shares of Orthofix International during the 3rd quarter valued at about $12,756,000. Paradice Investment Management LLC purchased a new position in shares of Orthofix International during the 2nd quarter valued at about $6,642,000. River Road Asset Management LLC purchased a new position in shares of Orthofix International during the 2nd quarter valued at about $6,419,000. State Street Corp lifted its position in shares of Orthofix International by 27.0% during the 1st quarter. State Street Corp now owns 462,479 shares of the medical device company’s stock valued at $17,640,000 after buying an additional 98,212 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Orthofix International by 11.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 870,120 shares of the medical device company’s stock valued at $40,443,000 after buying an additional 90,349 shares in the last quarter. 94.61% of the stock is currently owned by institutional investors and hedge funds.
Shares of Orthofix International (NASDAQ OFIX) opened at $52.81 on Tuesday. Orthofix International has a twelve month low of $32.51 and a twelve month high of $54.73. The company has a market capitalization of $984.29, a PE ratio of 35.29, a P/E/G ratio of 2.68 and a beta of 0.14.
Orthofix International Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.